Balance Sheet

Accounts Payables Accumulated Expenses Assets Capital Leases Cash & Current Investments Cash & Equivalents Common Equity Convertible Debt Current Assets Current Deferred Revenue Current Deferred Tax Assets Current Leases Current Taxes Finished Goods Goodwill Goodwill & Intangibles Intangibles Inventory Liabilities and Shareholders Equity Long-Term Deferred Tax Long-Term Investments Non-Current Assets Non-Current Debt Non-Current Deferred Tax Liability Non-Current Deffered Revenue Notes Payables Operating Leases Other Accumulated Expenses Other Non-Current Assets Other Non-Current Liabilities Payables Pension Preferred Shares Prepaid Assets Property, Plant & Equipment (Net)Raw Materials Receivables Receivables - Net Receivables - Other Retained Earnings Shareholder's Equity Short term Debt Short-term Investments Total Current Liabilities Total Debt Total Liabilities Total Non-Current Liabilities Treasury Shares Work In Process

Daily Values

Growth Metrics

Others

Supernus Pharmaceuticals (SUPN) Receivables - Other (2024 - 2025)

Historic Receivables - Other for Supernus Pharmaceuticals (SUPN) over the last 5 years, with Q3 2025 value amounting to $6.3 million.

Supernus Pharmaceuticals' Receivables - Other changed N/A to $6.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.3 million, marking a year-over-year change of. This contributed to the annual value of $4.0 million for FY2024, which is N/A changed from last year.
Supernus Pharmaceuticals' Receivables - Other amounted to $6.3 million in Q3 2025.
Supernus Pharmaceuticals' Receivables - Other's 5-year high stood at $6.3 million during Q3 2025, with a 5-year trough of $4.0 million in Q4 2024.